Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Other Operating Expenses (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Other Operating Expenses for 6 consecutive years, with $8.1 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 289.01% to $8.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.1 million through Dec 2025, up 244.37% year-over-year, with the annual reading at $21.0 million for FY2025, 440.54% up from the prior year.
  • Other Operating Expenses hit $8.1 million in Q4 2025 for BridgeBio Pharma, up from $6.6 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $8.1 million in Q4 2025 to a low of $109000.0 in Q2 2021.
  • Historically, Other Operating Expenses has averaged $1.9 million across 5 years, with a median of $739000.0 in 2022.
  • Biggest five-year swings in Other Operating Expenses: plummeted 58.28% in 2022 and later soared 997.49% in 2025.
  • Year by year, Other Operating Expenses stood at $1.6 million in 2021, then tumbled by 58.28% to $647000.0 in 2022, then dropped by 7.57% to $598000.0 in 2023, then soared by 248.49% to $2.1 million in 2024, then skyrocketed by 289.01% to $8.1 million in 2025.
  • Business Quant data shows Other Operating Expenses for BBIO at $8.1 million in Q4 2025, $6.6 million in Q3 2025, and $3.7 million in Q2 2025.